May 15, 2019
Powles T et al. Nature Medicine 2019;25:1706–1714.
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
You might also be interested by
Press Releases
Caprion-HistoGeneX expands its histological biomarker franchise by joining forces with Mosaic Laboratories
January 12, 2021
Histopathology
More infoScientific Publications
Biomarker recommendation for PD‐1/PD‐L1 immunotherapy development in pediatric cancer based on digital image analysis of PD‐L1 and immune cells
January 10, 2020
Histopathology
More infoScientific Publications
Digital pathology in immuno-oncology – a roadmap for clinical development
January 12, 2017
Histopathology
More info